Page last updated: 2024-12-05

4-nitroacetanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4-Nitroacetanilide is a yellow crystalline solid that is used in the synthesis of dyes and pharmaceuticals. It is prepared by the nitration of acetanilide. 4-Nitroacetanilide is a key intermediate in the production of many important compounds, including paracetamol (acetaminophen) and sulfanilamide. It has been shown to have antibacterial activity and is also a precursor to other compounds with medicinal properties. The compound is typically studied for its role in chemical synthesis and as a potential starting material for the development of new pharmaceuticals. It has been found to have various effects on the body, including anti-inflammatory and analgesic properties. The compound is of interest to researchers because of its potential applications in medicine and its ability to act as a building block for other important compounds.'

Cross-References

ID SourceID
PubMed CID7691
CHEMBL ID131469
SCHEMBL ID642700
MeSH IDM0104042

Synonyms (55)

Synonym
n-(4-nitrophenyl)-acetamide
nsc 1315
ccris 5566
ai3-01545
einecs 203-169-0
n-(4-nitrophenyl)acetamide
p-nitroacetanilide
nsc1315
p-acetamidonitrobenzene
4'-nitroacetanilide
wln: wnr dmv1
nsc-1315
104-04-1
p-nitrophenylacetanilide
n-acetyl-p-nitroaniline
acetanilide, p-nitro-
acetanilide, 4'-nitro-
acetamide, n-(4-nitrophenyl)-
4-nitroacetanilide
n-acetyl-4-nitroaniline
4-nitroacetanilide, 98%
MAYBRIDGE1_001346
STK004304
CHEMBL131469
HMS545F04
N0108
AKOS003237246
1-nitro-4-acetylaminobenzene;n-(4-nitrophenyl)acetamide
unii-ph3b066365
ph3b066365 ,
acetic acid 4-nitroanilide
FT-0619197
p-nitroacetanilide [mi]
SCHEMBL642700
p-acetamino nitrobenzene
n-(4-nitro-phenyl)-acetamide
DTXSID5059290
n-(p-nitrophenyl)acetamide
4-(acetylamino)nitrobenzene
1-nitro-4-acetylaminobenzene
n-acetyl-4-nitrobenzenamine
J-640230
W-109385
J-800231
mfcd00007303
10.14272/NQRLPDFELNCFHW-UHFFFAOYSA-N
doi:10.14272/nqrlpdfelncfhw-uhfffaoysa-n
Q7041448
AMY24805
7E-925
CS-0128761
AB9858
VYZ ,
SY106175
acetamide,n-(4-nitrophenyl)-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1160966Inhibition of West Nile virus NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160971Inhibition of wild-type Escherichia coli MurB compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160968Inhibition of Escherichia coli MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160965Inhibition of Dengue virus serotype 2 NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160969Inhibition of human MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160973Inhibition of wild-type Escherichia coli MurD compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160976GSH reactivity of the compound assessed as adducts formation by RP-HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160974Inhibition of wild-type Escherichia coli MurE compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160967Inhibition of Bovine thrombin using Boc-Val-Pro-Arg-AMC as substrate compound preincubated at 25 uM for 15 mins by fluorescence assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID147482In vitro inhibitory activity against H1N9 strain of Influenza neuraminidase (membrane) at 7 mM concentration1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID1160970Inhibition of wild-type Escherichia coli MurA compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160975Inhibition of wild-type Escherichia coli MurF compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1691499Inhibition of human mEH at 50 uM using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay relative to control2020European journal of medicinal chemistry, May-01, Volume: 193Development of potent inhibitors of the human microsomal epoxide hydrolase.
AID1160972Inhibition of wild-type Escherichia coli MurC compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's2 (18.18)18.2507
2000's3 (27.27)29.6817
2010's4 (36.36)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.29 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index75.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]